OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OMEICOS Therapeutics GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10960
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OMEICOS Therapeutics GmbH (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The company utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to develop therapeutics. Its clinical product candidate includes OMT-28, a synthetic small molecule analog of the omega-3 fatty acid metabolite 17, 18-EEQ which is developed for the treatment of paroxysmal and persistent atrial fibrillation, ventricular arrhythmia, myocardial infarction, macular edema diseases, and kidney injury. The company also conducts research and development activities. OMEICOS is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OMEICOS Therapeutics Raises USD19.34 Million in Series C Financing 11
OMEICOS Therapeutics Raises Additional Funds through Series B Financing 13
Omeicos Therapeutics Raises USD8.8 Million in Series B Financing 14
Omeicos Therapeutics Raises USD6.6 Million in Series A Venture Financing 16
Omeicos Therapeutics Secures Venture Funding 18
OMEICOS Therapeutics GmbH – Key Competitors 19
OMEICOS Therapeutics GmbH – Key Employees 20
OMEICOS Therapeutics GmbH – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Corporate Communications 22
Apr 27, 2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics 22
Product News 23
06/07/2017: OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases 23
04/27/2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics 24
Clinical Trials 25
Jul 17, 2018: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation 25
Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Key Facts 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OMEICOS Therapeutics Raises USD19.34 Million in Series C Financing 11
OMEICOS Therapeutics Raises Additional Funds through Series B Financing 13
Omeicos Therapeutics Raises USD8.8 Million in Series B Financing 14
Omeicos Therapeutics Raises USD6.6 Million in Series A Venture Financing 16
Omeicos Therapeutics Secures Venture Funding 18
OMEICOS Therapeutics GmbH, Key Competitors 19
OMEICOS Therapeutics GmbH, Key Employees 20
OMEICOS Therapeutics GmbH, Subsidiaries 21

List of Figures
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ameresco Inc (AMRC):企業の財務・戦略的SWOT分析
    Ameresco Inc (AMRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Surfnet:企業の戦略的SWOT分析
    Surfnet - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Biosearch Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biosearch Technologies Inc (Biosearch), a subsidiary of LGC Ltd is a biotechnology company that designs and manufactures regents. The company develops, and manufactures custom oligonucleotide-based tools. Its products include valupanel reagents, fluorogenic probes and primers, stellaries RNA …
  • The Hour Glass Ltd (AGS):企業の財務・戦略的SWOT分析
    The Hour Glass Ltd (AGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bayernoil Raffineriegesellschaft mbH:石油・ガス:M&Aディール及び事業提携情報
    Summary Bayernoil Raffineriegesellschaft mbH (Bayernoil) is an oil and gas company that offers refinery services to the oil and gas industry. The company provides products such as crude oil products, diesel, gasoline, fuel oil, bitumen, and others. It also offers liquefied fuels, heating oil, and sy …
  • Driver Group Plc (DRV):企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Porto Seguro SA:企業の戦略・SWOT・財務分析
    Porto Seguro SA - Strategy, SWOT and Corporate Finance Report Summary Porto Seguro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Veolia Environnement SA (VIE):電力:M&Aディール及び事業提携情報
    Summary Veolia Environnement SA (Veolia) is an environmental management services company that designs and offers water, waste and energy management solutions. Its service offerings include wastewater and sanitation services, drinking water treatment and distribution and waste management and energy s …
  • Ngai Hing Hong Co Ltd (1047)
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Chang Hwa Commercial Bank, Ltd.:企業の戦略・SWOT・財務情報
    Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Securitas AB:企業の戦略・SWOT・財務情報
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Gadeta BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Gadeta BV (Gadeta) is a biotechnology company, which focuses on the research and development of cellular immunotherapies for the elimination of cancer. The company’s technology platform combines alpha beta T cells engineered to express defined Gamma Delta T cell receptors (TEGs) that demonst …
  • GN Hearing AS:医療機器:M&Aディール及び事業提携情報
    Summary GN Hearing AS (GN Hearing) formerly, GN ReSound A/S, a subsidiary of GN Store Nord A/S, is a medical equipment company that provides advanced hearing health care solutions. The company offers hearing aids, accessories and related products. It also supplies computerized audiology and hearing …
  • Invenra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Invenra Inc (Invenra) is a biotechnology company that discovers and develops multispecific antibodies for immuno-oncology. The company’s pipeline products include t-cell redirecting b-bodies, OX40 agonist, treg depleter SNIPER and exelixis B-Body. Its B-Body and SNIPER technologies are used …
  • The Nature’s Bounty Co:企業の戦略的SWOT分析
    The Nature's Bounty Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As:企業の戦略・SWOT・財務分析
    Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report Summary Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Arc Logistics Partners LP (ARCX):石油・ガス:M&Aディール及び事業提携情報
    Summary Arc Logistics Partners LP (Arc Logistics Partners) is an oil and gas company that provides energy logistics services. The company owns and operates terminaling, storage, rail, transloading, and pipeline assets. It transports various products including gasoline, distillates, fuels, aviation g …
  • Suzuki Motor Corp (7269):企業の財務・戦略的SWOT分析
    Suzuki Motor Corp (7269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Halo Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Halo Pharma Inc (Halo) is a contract development and manufacturing organization which offers scientific and development expertise services. It offers project management, formulation development and analytical development services. The organization holds specialization in the development of m …
  • ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報
    Summary ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆